Related references
Note: Only part of the references are listed.A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors
Laura W. Goff et al.
CLINICAL CANCER RESEARCH (2016)
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2015)
Molecular Pathways: Can Activin-like Kinase Pathway Inhibition Enhance the Limited Efficacy of VEGF Inhibitors?
Rupal S. Bhatt et al.
CLINICAL CANCER RESEARCH (2014)
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2014)
Tivantinib: critical review with a focus on hepatocellular carcinoma
Elena Rota Caremoli et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Hepatocellular carcinoma: systemic therapies and future perspectives
Sameh Mikhail et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial
Andrew X. Zhu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Armando Santoro et al.
LANCET ONCOLOGY (2013)
Anti-human Activin Receptor-like Kinase 1 (ALK1) Antibody Attenuates Bone Morphogenetic Protein 9 (BMP9)-induced ALK1 Signaling and Interferes with Endothelial Cell Sprouting
Laurens A. van Meeteren et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
ALK1 as an emerging target for antiangiogenic therapy of cancer
Sara I. Cunha et al.
BLOOD (2011)
Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies
Dana D. Hu-Lowe et al.
CANCER RESEARCH (2011)
BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo
Yuka Suzuki et al.
JOURNAL OF CELL SCIENCE (2010)
Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis
Sara I. Cunha et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling
T Seki et al.
CIRCULATION RESEARCH (2003)
Mechanisms of TGF-β signaling from cell membrane to the nucleus
YG Shi et al.
CELL (2003)
A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2
S Srinivasan et al.
HUMAN MOLECULAR GENETICS (2003)
Arteriovenous malformations in mice lacking activin receptor-like kinase-1
LD Urness et al.
NATURE GENETICS (2000)
Share Paper
